Target intelligence / Profile preview

DNA mismatch repair protein MutS alpha complex (MutSα) (MutSα)

Target
MutSα
Molecular classification
DNA-binding protein, ATPase, Enzyme, DNA mismatch repair protein
01

Overview

The MutS alpha (MutSα) complex is a critical heterodimeric protein assembly composed of MSH2 and MSH6 subunits, serving as a primary sensor in the eukaryotic DNA mismatch repair (MMR) pathway [1][2]. It specifically recognizes single-base mismatches and small insertion-deletion loops (IDLs) that escape DNA polymerase proofreading during replication [2][3]. Upon binding to a mismatch, the complex utilizes its ATPase activity to undergo a conformational change, facilitating the recruitment of the MutL alpha complex to initiate the excision and resynthesis of the erroneous DNA strand [1][4]. Beyond repair, MutSα plays a pivotal role in signaling apoptosis in response to certain types of DNA damage, such as those induced by alkylating agents like temozolomide [5]. Mutations in the genes encoding MSH2 or MSH6 are a hallmark of Lynch syndrome, leading to microsatellite instability (MSI) and a significantly increased risk of colorectal, endometrial, and other cancers [6]. In oncology, the status of the MutSα complex is a vital biomarker; its deficiency renders tumors resistant to some conventional chemotherapies but highly sensitive to immune checkpoint inhibitors [7]. Furthermore, recent therapeutic developments have identified synthetic lethal targets, such as WRN helicase, which can be inhibited to selectively kill cells lacking functional MutSα [8].

Other names
MSH2-MSH6 complexMutS alphaMutS-alphaMutS-alpha complexMismatch repair complex 1
02

Mechanism of action

Recognition of DNA mismatches and DNA adducts to initiate repair or apoptosis; synthetic lethal interaction with WRN helicase inhibitors in deficient states.

03

Biological functions

DNA mismatch repairDNA damage recognitionMaintenance of genome stabilityApoptosis inductionMeiotic recombination
04

Disease associations

Lynch syndromeColorectal cancerEndometrial cancerMicrosatellite instability-high (MSI-H) cancerMuir-Torre syndrome
05

Safety considerations

Increased risk of hereditary cancer syndromes (Lynch syndrome)Potential for hypermutation and secondary malignancies if repair is compromisedResistance to alkylating agents in deficient cells
06

Interacting drugs

Temozolomide

4 more in the full profile.

07

Biomarkers

Microsatellite instability (MSI) statusMSH2 protein expressionMSH6 protein expressionMSH2 gene mutationMSH6 gene mutation

Beyond the preview

Go deeper on DNA mismatch repair protein MutS alpha complex (MutSα) (MutSα).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on DNA mismatch repair protein MutS alpha complex (MutSα) (MutSα).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call